Alkermes plc Stock
Alkermes plc Stock
There is an upward development for Alkermes plc compared to yesterday, with an increase of €1.09 (2.590%).
With 23 Buy predictions and 1 Sell predictions Alkermes plc is one of the favorites of our community.
With a target price of 47 € there is a slightly positive potential of 9.02% for Alkermes plc compared to the current price of 43.11 €.
Pros and Cons of Alkermes plc in the next few years
Pros
?
M***** P*******
?
S********** s********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | 2.590% | -10.125% | -8.572% | 72.769% | 77.161% | 52.591% | 93.565% |
| Icon plc | -8.080% | -3.975% | -5.459% | -9.534% | -7.228% | -37.172% | - |
| United Therapeutics | -0.520% | -2.019% | -3.756% | 84.880% | 6.740% | 104.989% | 194.258% |
| Ligand Pharmaceuticals | -1.540% | -3.759% | -7.246% | 118.803% | 54.217% | 316.260% | 167.056% |
Comments
Alkermes (ALKS) had its "overweight" rating reaffirmed by Piper Sandler.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its price target raised by Needham & Company LLC from $61.00 to $62.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Show more
Ratings data for ALKS provided by MarketBeat
News
Alkermes Q2 Earnings Call Highlights
Key Points
- Interested in Alkermes plc? Here are five stocks we like better.
- Alkermes reported strong Q2 performance: Revenue reached $496 million, while proprietary product sales rose 34% year
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
Key Points
- Interested in Alkermes plc? Here are five stocks we like better.
- Alkermes’ lead orexin agonist, alixorexton, has entered Phase 3 with the Brilliance program now enrolling in